TickerHumNASDAQ · Healthcare · Biotechnology
Moderna, Inc. (MRNA)
As of Nov 11, 4:00 PM ET, Moderna (MRNA) last traded at $248.69, down 0.85% on the day. Its TickerHum research score is 47/100 (average). It reported revenue of $2.53B for the twelve months ending 2026-09-30, up 13.1% year over year, with a -116.0% operating margin.
Ratings
- Valuation: 3/100 — Strongest input: price / earnings (ttm) Negative earnings. Weakest: free-cash-flow yield -2.0 %.
- Growth: 56/100 — Strongest input: revenue growth (ttm, yoy) +13.1 %. Weakest: diluted eps growth (ttm, yoy) +12.7 %.
- Profitability: 0/100 — Based on operating margin -116.0 %, net margin -110.5 %, return on equity -40.8 %.
- Financial health: 99/100 — Strongest input: current ratio 3.62. Weakest: long-term debt / equity 0.09.
- Momentum: 100/100 — Based on 3-month return +290.7 %, 6-month return +393.2 %, 1-year return +831.1 %, price vs 200-day average +162.9 %.
- Attention: 50/100 — Strongest input: headlines in the last 7 days 67. Weakest: volume vs 3-month average 0.3x.
- Risk resilience: 24/100 — Strongest input: max drawdown (1y) -34.2 %. Weakest: annualised volatility (1y) 130.3 %.
- Data confidence: 98/100 — Strongest input: quote age (hours) 3 h. Weakest: inputs available 95 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $2.53B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 13.1% | TTM ending 2026-09-30 · 10-Q |
| Net income | -$2.79B | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | -$7.04 | TTM ending 2026-09-30 · 10-Q |
| Operating margin | -116.0% | TTM ending 2026-09-30 · 10-Q |
| Net margin | -110.5% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | -$1.97B | TTM ending 2026-09-30 · 10-Q |
| Cash | $1.2B | as of 2026-09-30 · 10-Q |
| Long-term debt | $591M | as of 2026-06-30 · 10-Q |
| Debt / equity | 0.09 | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0001682852).
Comparable companies for Moderna
Selected by industry, business overlap and scale; these are not necessarily direct competitors.
- Moderna vs Vertex Pharmaceuticals (MRNA vs VRTX) — Same industry (Biotechnology); market cap 1.4x
- Moderna vs Regeneron Pharmaceuticals (MRNA vs REGN) — Same industry (Biotechnology); market cap unknown
- Moderna vs Pfizer (MRNA vs PFE) — Same sector (Healthcare), different industry; market cap 1.7x; shares: vaccines
- Moderna vs Merck & Co. (MRNA vs MRK) — Same sector (Healthcare), different industry; market cap 3.6x; shares: vaccines
- Moderna vs Bristol-Myers Squibb (MRNA vs BMY) — Same sector (Healthcare), different industry; market cap 1.3x
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.